B-cell chronic lymphoproliferative disorders: a clinical analysis of 40 cases
10.3760/cma.j.issn.1009-9921.2018.08.004
- VernacularTitle: B细胞慢性淋巴增殖性疾病40例临床分析
- Author:
Dehong WU
1
;
Pengfei WU
;
Hongchun QIU
;
Rong KONG
;
Haoxiang LU
;
Jie WU
Author Information
1. Department of Hematology, the Third People's Hospital of Kunshan, Kunshan 215300, China
- Publication Type:Journal Article
- Keywords:
B-cell chronic lymphoproliferative disease;
Clinical features;
Diagnosis;
Treatment
- From:
Journal of Leukemia & Lymphoma
2018;27(8):464-469
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features, treatment and prognosis of the patients with B-cell chronic lymphoproliferative disorders (B-CLPD).
Methods:The data of 40 patients with B-CLPD in the Third People's Hospital of Kunshan from September 2010 to June 2017 were retrospectively analyzed, including clinical features, laboratory inspections, immunophenotyping, genetics and molecules results, therapeutic regimens, evaluation of curative effect and disease outcome.
Results:There were 29 male and 11 female patients in 40 B-CLPD patients, with a median age of 71.5 years old (47-88 years old). The percentage of chronic lymphocytic leukemia (CLL) was 57.5% (23/40), monoclonal B lymphocytosis was 10.0% (4/40), Waldenstrom macroglobulinemia was 15.0% (6/40), marginal/splenic marginal zone lymphoma was 12.5% (5/40), and mantle cell lymphoma was 5.0% (2/40). The immunophenotyping of the whole patients had the expressions of CD19, and surface immunoglobulin light chain in cytomembrane of 37 patients had a restrictive expression. All CLL patients presented the expressions of CD5 and CD23, while the other types of B-CLPD expressed various level of CD20, CD22, CD10, CD5, FCM-7. Twenty-six patients received chemotherapies including purine analogue, anthracyclines, alkylating agents and hormone. The overall response rate (complete remission plus partial remission) was 69.2% (18/26). The complete remission rate was 15.4% (4/26), which only occurred in the cohort of CLL patients who received the regimen containing fludarabine. The median follow up time of 26 patients who received medical treatment was 42.8 months (0.5-82.0 months), not reaching the median survival time.
Conclusions:The clinical features of B-CLPD are various, which requires comprehensive analysis of clinical data, including medical history, laboratory findings, imageological examination, cell morphology, immunophenotyping, genetics as well as molecular biology. The choice of the treatment should take the individualized situation into consideration.
